PrEP Biopharm Ltd.
PrEP Biopharm is a development stage biopharmaceutical company that is creating a fundamentally new paradigm of prophylaxis for upper respiratory tract infections.
PrEP Biopharm Limited was spun out of Janssen (a Johnson & Johnson company) in 2015 with a worldwide exclusive license of PrEP 001. In November 2015 hVIVO acquired a significant equity stake in PrEP Biopharm.
Prior to this, in 2014 hVIVO conducted a proof of concept study for Janssen which demonstrated that their compound, now named PrEP-001, achieved a threefold reduction in clinical illness and an eightfold reduction in common cold symptoms compared with a placebo. With these promising results, hVIVO saw tremendous commercial potential for PrEP-001.
To learn more visit the PrEP Biopharm Ltd website here.
If you are interested to find out more about these and other hVIVO developments and innovations, and how there may be a collaborative or partnering opportunity with your organisation, then please use the “Contact Us” form on this website.